Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
09 Mai 2023 - 12:57PM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2023
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
09
May 2023 11:00 BST
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca
PLC (the Company) announces that, on 5 May 2023, it was
notified of a transaction in the Company's American Depositary
Shares (ADSs) by Aradhana Sarin, Chief Financial Officer and
Director of the Company, as set out below. Two ADSs are equivalent
to one of the Company's ordinary shares of $0.25
each.
|
PDMR
|
Position
|
Nature of the transaction
|
Quantity
|
Price
|
|
Aradhana
Sarin
|
Chief
Financial Officer
|
Sale of
ADSs
|
19,470
|
US$74.81
|
Further
details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Aradhana
Sarin
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief
Financial Officer
|
|
b)
|
Initial
notification /Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca
PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
Identification
code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
|
|
b)
|
Nature
of the transaction
|
Sale of AstraZeneca PLC American Depositary Shares
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
US$74.81
|
19,470
|
|
d)
|
Aggregated
information
-
Aggregated volume
-
Price
|
Not
applicable - single transaction
|
|
e)
|
Date
of the transaction
|
5 May
2023
|
|
f)
|
Place
of the transaction
|
XNAS
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
9 May 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Aug 2023 bis Sep 2023
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Sep 2022 bis Sep 2023
